Skip to main content
Erschienen in: Pediatric Nephrology 2/2020

02.09.2019 | Original Article

C3 levels and acute outcomes in Shiga toxin–related hemolytic uremic syndrome

verfasst von: Alejandro Balestracci, Luciana Meni Bataglia, Ismael Toledo, Laura Beaudoin, Caupolican Alvarado

Erschienen in: Pediatric Nephrology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The correlation between complement activation and severity of hemolytic uremic syndrome related to Shiga toxin–producing Escherichia coli (STEC-HUS) has been examined in few studies, with conflicting results. We investigated whether C3 levels on admission are associated with worse acute outcomes.

Methods

Demographic, clinical, and laboratory variables were compared between dialyzed and non-dialyzed patients and between those with or without extrarenal complications. Univariate and multivariate analyses were performed; odds ratio (OR) and 95% confidence interval (95%CI) were calculated. C3 concentrations were correlated with dialysis length (Spearman test) and ROC curves with area under the curves (AUC) were calculated to identify C3 concentrations able to discriminate patients with dialysis requirements and complicated course.

Results

Among 49 children, 33 had normal and 16 had decreased C3 concentrations. Higher hemoglobin, lactic dehydrogenase, urea and creatinine and lower albumin, sodium, and C3 and C4 concentrations at admission were associated with dialysis requirement; only creatinine remained significant (p = 0.03, OR 2.1, 95%CI 1.34–2.7) by multivariate analysis. Patients with a complicated course presented higher leukocyte count, hemoglobin and lactic dehydrogenase and lower albumin, sodium, and C3 and C4. In the multivariate analysis, leukocyte count (p = 0.02, OR 2.6, 95%CI 1.4–4.3) and C3 concentration (p = 0.039, OR 1.7, 95%CI 1.1–2.73) were independently associated with a complicated disease. C3 levels correlated with dialysis length (r = − 0.42, p = 0.002); nevertheless, they were unable to discriminate dialysis requirement (AUC = 0.25, 95%CI 0.11–0.38) and extrarenal complications (AUC = 0.24, 95%CI 0.11–0.4).

Conclusions

Our study suggests that decreased C3 levels at admission are associated with a more complicated STEC-HUS episode.
Literatur
1.
2.
Zurück zum Zitat Percheron L, Gramada R, Tellier S, Salomon R, Harambat J, Llanas B, Fila M, Allain-Launay E, Lapeyraque AL, Leroy V, Adra AL, Bérard E, Bourdat-Michel G, Chehade H, Eckart P, Merieau E, Piètrement C, Sellier-Leclerc AL, Frémeaux-Bacchi V, Dimeglio C, Garnier A (2018) Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 33(8):1385–1394PubMed Percheron L, Gramada R, Tellier S, Salomon R, Harambat J, Llanas B, Fila M, Allain-Launay E, Lapeyraque AL, Leroy V, Adra AL, Bérard E, Bourdat-Michel G, Chehade H, Eckart P, Merieau E, Piètrement C, Sellier-Leclerc AL, Frémeaux-Bacchi V, Dimeglio C, Garnier A (2018) Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 33(8):1385–1394PubMed
3.
Zurück zum Zitat Keir LS, Saleem MA (2014) Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 29(10):1895–1902PubMed Keir LS, Saleem MA (2014) Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 29(10):1895–1902PubMed
4.
Zurück zum Zitat Poolpol K, Orth-Höller D, Speth C, Zipfel PF, Skerka C, de Córdoba SR, Brockmeyer J, Bielaszewska M, Würzner R (2014) Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 58(1):77–84PubMed Poolpol K, Orth-Höller D, Speth C, Zipfel PF, Skerka C, de Córdoba SR, Brockmeyer J, Bielaszewska M, Würzner R (2014) Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 58(1):77–84PubMed
5.
Zurück zum Zitat Orth-Höller D, Würzner R (2014) Role of complement in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Semin Thromb Hemost 40(4):503–507PubMed Orth-Höller D, Würzner R (2014) Role of complement in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Semin Thromb Hemost 40(4):503–507PubMed
6.
Zurück zum Zitat Kaplan BS, Thomson PD, MacNab GM (1973) Letter: serum-complement levels in haemolytic-uraemic syndrome. Lancet 2(7844):1505–1506PubMed Kaplan BS, Thomson PD, MacNab GM (1973) Letter: serum-complement levels in haemolytic-uraemic syndrome. Lancet 2(7844):1505–1506PubMed
7.
Zurück zum Zitat Monnens L, Molenaar J, Lambert PH, Proesmans W, van Munster P (1980) The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 13(4):168–171PubMed Monnens L, Molenaar J, Lambert PH, Proesmans W, van Munster P (1980) The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 13(4):168–171PubMed
8.
Zurück zum Zitat Cameron JS, Vick R (1973) Letter: plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet 2(7835):975PubMed Cameron JS, Vick R (1973) Letter: plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet 2(7835):975PubMed
9.
Zurück zum Zitat Monnens L, Hendrickx G, van Wieringen P, van Munster P (1974) Letter: serum-complement levels in haemolytic-uraemic syndrome. Lancet 2(7875):294PubMed Monnens L, Hendrickx G, van Wieringen P, van Munster P (1974) Letter: serum-complement levels in haemolytic-uraemic syndrome. Lancet 2(7875):294PubMed
10.
Zurück zum Zitat Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Würzner R (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182(10):6394–6400PubMed Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Würzner R (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182(10):6394–6400PubMed
11.
Zurück zum Zitat He X, Quiñones B, Loo MT, Loos S, Scavia G, Brigotti M, Levtchenko E, Monnens L (2015) Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome. Acta Paediatr 104(12):e564–e568PubMed He X, Quiñones B, Loo MT, Loos S, Scavia G, Brigotti M, Levtchenko E, Monnens L (2015) Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome. Acta Paediatr 104(12):e564–e568PubMed
12.
Zurück zum Zitat Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C (2011) Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187(1):172–180PubMed Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C (2011) Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187(1):172–180PubMed
13.
Zurück zum Zitat Ståhl AL, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117(20):5503–5513PubMed Ståhl AL, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117(20):5503–5513PubMed
14.
Zurück zum Zitat Arvidsson I, Ståhl AL, Hedström MM, Kristoffersson AC, Rylander C, Westman JS, Storry JR, Olsson ML, Karpman D (2015) Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol 194(5):2309–2318PubMed Arvidsson I, Ståhl AL, Hedström MM, Kristoffersson AC, Rylander C, Westman JS, Storry JR, Olsson ML, Karpman D (2015) Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol 194(5):2309–2318PubMed
15.
Zurück zum Zitat Arvidsson I, Rebetz J, Loos S, Herthelius M, Kristoffersson AC, Englund E, Chromek M, Karpman D (2016) Early terminal complement blockade and C6 deficiency are protective in enterohemorrhagic Escherichia coli-infected mice. J Immunol 197(4):1276–1286PubMed Arvidsson I, Rebetz J, Loos S, Herthelius M, Kristoffersson AC, Englund E, Chromek M, Karpman D (2016) Early terminal complement blockade and C6 deficiency are protective in enterohemorrhagic Escherichia coli-infected mice. J Immunol 197(4):1276–1286PubMed
16.
Zurück zum Zitat Zoja C, Buelli S, Morigi M (2019) Shiga toxin triggers endothelial and podocyte injury: the role of complement activation. Pediatr Nephrol 34(3):379–388PubMed Zoja C, Buelli S, Morigi M (2019) Shiga toxin triggers endothelial and podocyte injury: the role of complement activation. Pediatr Nephrol 34(3):379–388PubMed
17.
Zurück zum Zitat Ehrlenbach S, Rosales A, Posch W, Wilflingseder D, Hermann M, Brockmeyer J, Karch H, Satchell SC, Würzner R, Orth-Höller D (2013) Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immum 81(8):2678–2685 Ehrlenbach S, Rosales A, Posch W, Wilflingseder D, Hermann M, Brockmeyer J, Karch H, Satchell SC, Würzner R, Orth-Höller D (2013) Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immum 81(8):2678–2685
18.
Zurück zum Zitat Robson WL, Leung AK, Fick GH, McKenna AI (1992) Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 62(3):296–299PubMed Robson WL, Leung AK, Fick GH, McKenna AI (1992) Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 62(3):296–299PubMed
19.
Zurück zum Zitat Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H (2009) Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4(12):1920–1924PubMedPubMedCentral Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H (2009) Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4(12):1920–1924PubMedPubMedCentral
20.
Zurück zum Zitat Ferraris JR, Ferraris V, Acquier AB, Sorroche PB, Saez MS, Ginaca A, Mendez CF (2015) Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. Clin Exp Immunol 181(1):118–125PubMedPubMedCentral Ferraris JR, Ferraris V, Acquier AB, Sorroche PB, Saez MS, Ginaca A, Mendez CF (2015) Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. Clin Exp Immunol 181(1):118–125PubMedPubMedCentral
21.
Zurück zum Zitat Ahlenstiel-Grunow T, Hachmeister S, Bange FC, Wehling C, Kirschfink M, Bergmann C, Pape L (2016) Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome. Nephrol Dial Transplant 31:1114–1121PubMed Ahlenstiel-Grunow T, Hachmeister S, Bange FC, Wehling C, Kirschfink M, Bergmann C, Pape L (2016) Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome. Nephrol Dial Transplant 31:1114–1121PubMed
22.
Zurück zum Zitat Ağbaş A, Göknar N, Akıncı N, Yıldırım ZY, Taşdemir M, Benzer M, Gökçe İ, Candan C, Küçük N, Uzuner S, Özçelik G, Demirkol D, Sever L, Çalışkan S (2018) Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab. Pediatr Nephrol 33(12):2371–2381PubMed Ağbaş A, Göknar N, Akıncı N, Yıldırım ZY, Taşdemir M, Benzer M, Gökçe İ, Candan C, Küçük N, Uzuner S, Özçelik G, Demirkol D, Sever L, Çalışkan S (2018) Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab. Pediatr Nephrol 33(12):2371–2381PubMed
23.
Zurück zum Zitat Karnisova L, Hradsky O, Blahova K, Fencl F, Dolezel Z, Zaoral T, Zieg J (2018) Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study. Eur J Pediatr 177(12):1837–1844PubMed Karnisova L, Hradsky O, Blahova K, Fencl F, Dolezel Z, Zaoral T, Zieg J (2018) Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study. Eur J Pediatr 177(12):1837–1844PubMed
24.
Zurück zum Zitat Frémeaux-Bacchi V, Sellier-Leclerc AL, Vieira-Martins P, Limou S, Kwon T, Lahoche A, Novo R, Llanas B, Nobili F, Roussey G, Cailliez M, Ulinski T, Deschênes G, Alberti C, Weill FX, Mariani P, Loirat C (2019) Complement gene variants and Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome: retrospective genetic and clinical study. Clin J Am Soc Nephrol 14(3):364–377PubMedPubMedCentral Frémeaux-Bacchi V, Sellier-Leclerc AL, Vieira-Martins P, Limou S, Kwon T, Lahoche A, Novo R, Llanas B, Nobili F, Roussey G, Cailliez M, Ulinski T, Deschênes G, Alberti C, Weill FX, Mariani P, Loirat C (2019) Complement gene variants and Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome: retrospective genetic and clinical study. Clin J Am Soc Nephrol 14(3):364–377PubMedPubMedCentral
25.
Zurück zum Zitat Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE (2012) Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol 27(8):1407–1410PubMed Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE (2012) Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol 27(8):1407–1410PubMed
26.
Zurück zum Zitat Alconcher LF, Coccia PA, Suarez ADC, Monteverde ML, Perez Y, Gutiérrez MG, Carlopio PM, Missoni ML, Balestracci A, Principi I, Ramírez FB, Estrella P, Micelli S, Leroy DC, Quijada NE, Seminara C, Giordano MI, Hidalgo Solís SB, Saurit M, Caminitti A, Arias A, Rivas M, Risso P, Liern M (2018) Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome. Pediatr Nephrol 33(10):1791–1798PubMed Alconcher LF, Coccia PA, Suarez ADC, Monteverde ML, Perez Y, Gutiérrez MG, Carlopio PM, Missoni ML, Balestracci A, Principi I, Ramírez FB, Estrella P, Micelli S, Leroy DC, Quijada NE, Seminara C, Giordano MI, Hidalgo Solís SB, Saurit M, Caminitti A, Arias A, Rivas M, Risso P, Liern M (2018) Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome. Pediatr Nephrol 33(10):1791–1798PubMed
27.
Zurück zum Zitat Balestracci A, Meni Battaglia L, Toledo I, Martin SM, Alvarado C (2018) Blood urea nitrogen to serum creatinine ratio as a prognostic factor in diarrhea-associated hemolytic uremic syndrome: a validation study. Eur J Pediatr 177:63–68PubMed Balestracci A, Meni Battaglia L, Toledo I, Martin SM, Alvarado C (2018) Blood urea nitrogen to serum creatinine ratio as a prognostic factor in diarrhea-associated hemolytic uremic syndrome: a validation study. Eur J Pediatr 177:63–68PubMed
28.
Zurück zum Zitat Flynn JT, Kaelber DC, Baker-Smith CM, SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140(3):e20171904PubMed Flynn JT, Kaelber DC, Baker-Smith CM, SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140(3):e20171904PubMed
29.
Zurück zum Zitat Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Piètrement C, Champion G, Ulinski T, Deschênes G (2010) Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5(7):1218–1228PubMedPubMedCentral Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Piètrement C, Champion G, Ulinski T, Deschênes G (2010) Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5(7):1218–1228PubMedPubMedCentral
30.
Zurück zum Zitat Rahman RC, Cobeñas CJ, Drut R, Amoreo OR, Ruscasso JD, Spizzirri AP, Suarez Adel C, Zalba JH, Ferrari C, Gatti MC (2012) Hemorrhagic colitis in postdiarrheal hemolytic uremic syndrome: retrospective analysis of 54 children. Pediatr Nephrol 27(2):229–233PubMed Rahman RC, Cobeñas CJ, Drut R, Amoreo OR, Ruscasso JD, Spizzirri AP, Suarez Adel C, Zalba JH, Ferrari C, Gatti MC (2012) Hemorrhagic colitis in postdiarrheal hemolytic uremic syndrome: retrospective analysis of 54 children. Pediatr Nephrol 27(2):229–233PubMed
31.
Zurück zum Zitat Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis (2005) International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6(1):2–8PubMed Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis (2005) International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6(1):2–8PubMed
32.
Zurück zum Zitat Srinath AI, Lowe ME (2013) Pediatric pancreatitis. Pediatr Rev 34(2):79–90PubMed Srinath AI, Lowe ME (2013) Pediatric pancreatitis. Pediatr Rev 34(2):79–90PubMed
33.
Zurück zum Zitat Suri RS, Clark WF, Barrowman N, Mahon JL, Thiessen-Philbrook HR, Rosas-Arellano MP, Zarnke K, Garland JS, Garg AX (2005) Diabetes during diarrhea-associated hemolytic uremic syndrome: a systematic review and meta-analysis. Diabetes Care 28(10):2556–2562PubMed Suri RS, Clark WF, Barrowman N, Mahon JL, Thiessen-Philbrook HR, Rosas-Arellano MP, Zarnke K, Garland JS, Garg AX (2005) Diabetes during diarrhea-associated hemolytic uremic syndrome: a systematic review and meta-analysis. Diabetes Care 28(10):2556–2562PubMed
34.
Zurück zum Zitat KDIGO CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl:1–150 KDIGO CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl:1–150
35.
Zurück zum Zitat Balestracci A, Toledo I, Meni Battaglia L, de Lillo L, More N, Cao G, Alvarado C (2017) Postdiarrhoeal haemolytic uraemic syndrome without thrombocytopenia. Nefrologia 37(5):508–514PubMed Balestracci A, Toledo I, Meni Battaglia L, de Lillo L, More N, Cao G, Alvarado C (2017) Postdiarrhoeal haemolytic uraemic syndrome without thrombocytopenia. Nefrologia 37(5):508–514PubMed
36.
Zurück zum Zitat Oakes RS, Siegler RL, McReynolds MA, Pysher T, Pavia AT (2006) Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 117:1656–1662PubMed Oakes RS, Siegler RL, McReynolds MA, Pysher T, Pavia AT (2006) Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 117:1656–1662PubMed
37.
Zurück zum Zitat Mody RK, Gu W, Griffin PM, Jones TF, Rounds J, Shiferaw B, Tobin-D’Angelo M, Smith G, Spina S, Hurd S, Lathrop S, Palmer A, Boothe E, Luna-Gierke RE, Hoekstra RM (2015) Post diarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr 166:1022–1029PubMed Mody RK, Gu W, Griffin PM, Jones TF, Rounds J, Shiferaw B, Tobin-D’Angelo M, Smith G, Spina S, Hurd S, Lathrop S, Palmer A, Boothe E, Luna-Gierke RE, Hoekstra RM (2015) Post diarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr 166:1022–1029PubMed
38.
Zurück zum Zitat Ardissino G, Daccò V, Testa S, Civitillo CF, Tel F, Possenti I, Belingheri M, Castorina P, Bolsa-Ghiringhelli N, Tedeschi S, Paglialonga F, Salardi S, Consonni D, Zoia E, Salice P, Chidini G (2015) Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremicsyndrome. Pediatr Nephrol 30(2):345–352PubMed Ardissino G, Daccò V, Testa S, Civitillo CF, Tel F, Possenti I, Belingheri M, Castorina P, Bolsa-Ghiringhelli N, Tedeschi S, Paglialonga F, Salardi S, Consonni D, Zoia E, Salice P, Chidini G (2015) Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremicsyndrome. Pediatr Nephrol 30(2):345–352PubMed
39.
Zurück zum Zitat Grisaru S, Xie J, Samuel S, Hartling L, Tarr PI, Schnadower D, Freedman SB, Alberta Provincial Pediatric Enteric Infection Team (2017) Associations between hydration status, intravenous fluid administration, and outcomes of patients infected with Shiga toxin-producing Escherichia coli: a systematic review and meta-analysis. JAMA Pediatr 171(1):68–76PubMed Grisaru S, Xie J, Samuel S, Hartling L, Tarr PI, Schnadower D, Freedman SB, Alberta Provincial Pediatric Enteric Infection Team (2017) Associations between hydration status, intravenous fluid administration, and outcomes of patients infected with Shiga toxin-producing Escherichia coli: a systematic review and meta-analysis. JAMA Pediatr 171(1):68–76PubMed
40.
Zurück zum Zitat Serebruany VL, Christenson MJ, Pescetti J, McLean RH (1993) Hypoproteinemia in the hemolytic-uremic syndrome of childhood. Pediatr Nephrol 7(1):72–73PubMed Serebruany VL, Christenson MJ, Pescetti J, McLean RH (1993) Hypoproteinemia in the hemolytic-uremic syndrome of childhood. Pediatr Nephrol 7(1):72–73PubMed
41.
Zurück zum Zitat Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS (2013) Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28(11):2097–2105PubMed Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS (2013) Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28(11):2097–2105PubMed
42.
Zurück zum Zitat Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC (2017) Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 32(2):297–309PubMed Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC (2017) Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 32(2):297–309PubMed
43.
Zurück zum Zitat Charchaflieh J, Rushbrook J, Worah S, Zhang M (2015) Activated complement factors as disease markers for Sepsis. Dis Markers 2015:382463PubMedPubMedCentral Charchaflieh J, Rushbrook J, Worah S, Zhang M (2015) Activated complement factors as disease markers for Sepsis. Dis Markers 2015:382463PubMedPubMedCentral
44.
Zurück zum Zitat Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364(26):2561–2563PubMed Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364(26):2561–2563PubMed
45.
Zurück zum Zitat Keenswijk W, Raes A, Vande Walle J (2018) Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Eur J Pediatr 177(3):311–318PubMed Keenswijk W, Raes A, Vande Walle J (2018) Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Eur J Pediatr 177(3):311–318PubMed
Metadaten
Titel
C3 levels and acute outcomes in Shiga toxin–related hemolytic uremic syndrome
verfasst von
Alejandro Balestracci
Luciana Meni Bataglia
Ismael Toledo
Laura Beaudoin
Caupolican Alvarado
Publikationsdatum
02.09.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 2/2020
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-019-04334-3

Weitere Artikel der Ausgabe 2/2020

Pediatric Nephrology 2/2020 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.